|Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update|
"2017 is off to a great start for Audentes, highlighted by the
Mr. Patterson continued, "Our primary, near-term goals are to initiate ASPIRO and VALENS, the phase 1 / 2 studies of AT132 for XLMTM and AT342 for Crigler-Najjar, and to report preliminary data from each study by year-end 2017. We are also on track to file INDs to evaluate the systemic administration of AT982 for the treatment of Pompe disease and AT307 for the treatment of CPVT. As a result, in 2018 we plan to be conducting clinical trials in each of our four development programs."
Upcoming Planned Events
First Quarter 2017 Financial Results
For more information regarding Audentes, please visit www.audentestx.com.
Forward Looking Statements
Selected Financial Information
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-reports-first-quarter-2017-financial-results-and-provides-corporate-update-300455779.html
Investors + Media